TR1801-ADC in Patients With Tumors That Express c-Met - Trial NCT03859752
Access comprehensive clinical trial information for NCT03859752 through Pure Global AI's free database. This Phase 1 trial is sponsored by Tanabe Research Laboratories USA Inc and is currently Not yet recruiting. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Tanabe Research Laboratories USA Inc
Timeline & Enrollment
Phase 1
Aug 14, 2019
Mar 31, 2023
Primary Outcome
Characterize safety of TR1801-ADC in patients with advanced solid tumor malignancies which express c-Met,Establish maximum tolerated dose
Summary
First-in-human, Phase 1 study to assess safety, tolerability, and pharmacokinetics of
 TR1801-ADC in patients with select solid tumors that express c-Met.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03859752
Non-Device Trial